Cardiogen vs HGH
Moderate Research vs FDA Approved
synergistic Mechanism-based · 47% Cardiogen and HGH work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
Cardiogen HGH
Weight 460 Da 22,124 Da
Half-life Minutes (short peptide); effects persist via epigenetic changes 3-4 hours (SC), 20-30 minutes (IV)
Chain 4 amino acids 191 amino acids
Type Tetrapeptide bioregulator Single-chain polypeptide with two disulfide bridges
Key Benefits
Cardiogen
01 Supports cardiac tissue repair and regeneration
02 Regulates cardiovascular gene expression
03 Improves myocardial function
04 May support post-cardiac event recovery
05 Epigenetic mechanism for targeted action
06 Works at DNA/nuclear level
07 Part of comprehensive anti-aging protocols
08 Well-researched Khavinson peptide
HGH
01 Improved body composition (increased lean mass, decreased fat)
02 Enhanced bone mineral density
03 Improved lipid profile
04 Increased exercise capacity
05 Better quality of life and mood
06 Skin, hair, and nail improvements
07 Enhanced recovery and healing
Dosing Protocols
Cardiogen
10-20 mg daily / Once daily for 10-20 consecutive days
Research protocol 10 mg Daily for 10 days
HGH
1-4 IU daily (0.33-1.33mg); start low and titrate up / Once daily or split into 2 doses (morning and evening)
Medical GHD (Starting) 0.15-0.3mg/day (0.5-1 IU) Once daily
Medical GHD (Maintenance) 0.4-0.8mg/day (1.2-2.4 IU) Once daily
Anti-Aging/Wellness 1-2 IU/day (0.33-0.67mg) Once daily
Body Recomposition 2-4 IU/day (0.67-1.33mg) Once or twice daily
Performance (Higher Risk) 4-8 IU/day (1.33-2.67mg) Split twice daily
Side Effects
Cardiogen
Generally well-tolerated
Minimal side effects reported
HGH
Water retention and fluid accumulation
Joint pain and stiffness
Carpal tunnel syndrome (usually resolves with dose reduction)
Headaches
Numbness/tingling in hands
Contraindications
Active cardiac emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Active cancer (may accelerate tumor growth)
Acute critical illness (increased mortality in ICU patients)
Closed epiphyses in children (for growth promotion)
Pregnancy/breastfeeding
Research Evidence
Cardiogen HGH
Status Moderate Research FDA Approved
References 3 studies 4 studies
Latest — 2024
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.